Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

QR Code

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +81-29-295-5400Email m-katou@kensei-kai.comPur...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2020
Sujets:	dpp-4 inhibitor α-glucosidase inhibitor metformin egfr slope type 2 diabetes Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/8b5d79d40e3f4f0ba712bb5cf5f548e4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
par: Marina Vladimirovna Shestakova
Publié: (2010)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
par: Alexander Sergeevich Ametov, et autres
Publié: (2010)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
par: Editorial team Diabetes Mellitus
Publié: (2012)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
par: Karyekar CS, et autres
Publié: (2013)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
par: Karina Oganesovna Galstyan, et autres
Publié: (2016)

Vildagliptin: the first innovative DDP-4 inhibitor
par: Edvin Villkhauer
Publié: (2010)

DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
par: De Nigris V, et autres
Publié: (2021)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
par: Taehwan Park, et autres
Publié: (2021)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
par: Mohammed A. S. Abourehab, et autres
Publié: (2021)

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
par: Tarek S. Ibrahim, et autres
Publié: (2021)

New Multi-Targeted Antiproliferative Agents: Design and Synthesis of IC261-Based Oxindoles as Potential Tubulin, CK1 and EGFR Inhibitors
par: Momen R. Fareed, et autres
Publié: (2021)

Health-promoting activities of edible seaweed extracts from Chilean coasts: assessment of antioxidant, anti-diabetic, anti-inflammatory and antimicrobial potential
par: García,Vivian, et autres
Publié: (2020)

IN VITRO EFFECT OF TERPENOIDS - RICH EXTRACT OF Momordica charantia ON ALPHA GLUCOSIDASE ACTIVITY
par: A. B. SALLAU, et autres

In vitro effect of terpenoid-rich extract of Momordica charantia on alpha glucosidase activity
par: AB SALLAU, et autres
Publié: (2018)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
par: Lyudmila Viktorovna Nedosugova, et autres
Publié: (2014)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
par: Kuecker CM, et autres
Publié: (2016)

Nanozymes as Enzyme Inhibitors
par: Huang Y, et autres
Publié: (2021)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
par: Taras S. Panevin, et autres
Publié: (2020)

Linagliptin use in older individuals with type 2 diabetes
par: Pratley RE
Publié: (2014)

SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT
par: Rashid,Mohammad, et autres
Publié: (2020)

Diffuse scaly erythematous plaques in patient taking poziotinib
par: Reid Oldenburg, MD, PhD, et autres
Publié: (2022)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
par: Shen L, et autres
Publié: (2021)

Teneligliptin in management of type 2 diabetes mellitus
par: Sharma SK, et autres
Publié: (2016)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
par: Nathaniel Wiest, et autres
Publié: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
par: Wolfram Samlowski, et autres
Publié: (2021)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
par: James M. Henderson, et autres
Publié: (2021)

Protease Inhibitor and Metabolic Alteration
par: Cavenaghi,F. M, et autres
Publié: (2012)

Effect of Nitrogen Inhibitors on Nitrous Oxide Emissions and Pasture Growth After an Autumn Application in Volcanic Soil
par: Vistoso,Erika, et autres
Publié: (2012)

Phytochemical Screening and Antioxidant Activity of Seven Native Species Growing in the Forests of Southern Chilean Patagonia
par: Merly de Armas-Ricard, et autres
Publié: (2021)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
par: Yu D, et autres
Publié: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
par: Whitney E. Lewis, PharmD, et autres
Publié: (2021)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
par: Sergey V. Kakorin, et autres
Publié: (2016)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
par: Elena Valer'evna Biryukova
Publié: (2014)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
par: Ghosh S, et autres
Publié: (2016)

COX-2 Inhibitors in Dental Pain Management
par: Del-Muro-Casas,Fatima Erendida, et autres
Publié: (2018)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
par: Kate S, et autres
Publié: (2019)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
par: Tory Starzyk, MA, et autres
Publié: (2022)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
par: Wiktoria Blaszczak, et autres
Publié: (2021)

The serine protease inhibitors and plant-insect interaction
par: Mendoza-Blanco,Werner, et autres
Publié: (2012)